OTCMKTS:PVCT Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free PVCT Stock Alerts $0.19 0.00 (0.00%) (As of 04/19/2024 ET) Add Compare Share Share Today's Range$0.18▼$0.1950-Day Range$0.13▼$0.2252-Week Range$0.06▼$0.22Volume198,647 shsAverage Volume297,872 shsMarket Capitalization$81.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Provectus Biopharmaceuticals alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT)Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Read More PVCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PVCT Stock News HeadlinesApril 18, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor CancersApril 16, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value CreationApril 19, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 27, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal SodiumMarch 12, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and VaccinesMarch 7, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual MeetingFebruary 29, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual MeetingFebruary 23, 2024 | finance.yahoo.comProvectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call TranscriptApril 19, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 15, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces First Quarter 2024 Conference CallFebruary 15, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces First Quarter 2024 Conference CallFebruary 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Engages irlabs for Investor Relations ServicesFebruary 14, 2024 | globenewswire.comProvectus Biopharmaceuticals Engages irlabs for Investor Relations ServicesDecember 18, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine AdjuvantNovember 19, 2023 | morningstar.comProvectus Biopharmaceuticals Inc PVCTNovember 15, 2023 | finanznachrichten.deProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous MelanomaNovember 15, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous MelanomaNovember 13, 2023 | finanznachrichten.deProvectus Biopharmaceuticals Inc.: Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal MelanomaNovember 13, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal MelanomaNovember 6, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNovember 2, 2023 | benzinga.comProvectus Algae Enters Into Livestock Methane Reduction Space Commissioning First Demonstration Biomanufacturing PlantAugust 7, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingAugust 1, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 CongressJune 28, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue SarcomasJune 3, 2023 | finance.yahoo.comPVCT - Provectus Biopharmaceuticals, Inc.May 12, 2023 | chron.comProvectus: Q1 Earnings SnapshotApril 20, 2023 | finance.yahoo.comProvectus Biopharmaceuticals Announces Publication of Activity of Pharmaceutical-Grade Rose Bengal Sodium (RBS) Against Colistin-Resistant Gram-Negative BacteriaSee More Headlines Receive PVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/19/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CUSIPN/A CIK315545 Webwww.provectusbio.com Phone(866) 594-5999Fax866-998-0005Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,100,000.00 Net Margins-555.91% Pretax Margin-555.91% Return on EquityN/A Return on Assets-189.49% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual Sales$560,000.00 Price / Sales145.93 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-9.74Miscellaneous Outstanding Shares419,500,000Free Float369,157,000Market Cap$81.72 million OptionableNot Optionable Beta0.67 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Dominic Rodrigues C.F.A. (Age 55)CFA, Chief Operations Consultant & Vice Chairman of the Board Comp: $75kDr. Eric A. Wachter (Age 61)Co-Founder & CTO Comp: $174.19kMs. Heather Raines CPA (Age 57)Chief Financial Officer Comp: $83.33kKey CompetitorsCarisma TherapeuticsNASDAQ:CARMRallybioNASDAQ:RLYBCorvus PharmaceuticalsNASDAQ:CRVSImmix BiopharmaNASDAQ:IMMXCelularityNASDAQ:CELUView All Competitors PVCT Stock Analysis - Frequently Asked Questions How have PVCT shares performed in 2024? Provectus Biopharmaceuticals' stock was trading at $0.0960 at the beginning of 2024. Since then, PVCT shares have increased by 102.9% and is now trading at $0.1948. View the best growth stocks for 2024 here. Are investors shorting Provectus Biopharmaceuticals? Provectus Biopharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 190,800 shares, an increase of 1,700.0% from the March 15th total of 10,600 shares. Based on an average daily volume of 649,000 shares, the days-to-cover ratio is presently 0.3 days. View Provectus Biopharmaceuticals' Short Interest. When is Provectus Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our PVCT earnings forecast. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA), Energy Transfer (ET), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB) and MaxLinear (MXL). How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PVCT) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle PublishingHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.